Open AccessRituximab treatment for fibrillary glomerulonephritis
Author(s) -
John Hogan,
Michaela D. Restivo,
Pietro A. Canetta,
Leal Herlitz,
Jai Radhakrishnan,
Gerald B. Appel,
Andrew S. Bomback
Publication year - 2014
Publication title -
nephrology dialysis transplantation
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfu189
Subject(s) - rituximab , medicine , immunosuppression , proteinuria , renal function , gastroenterology , creatinine , kidney disease , surgery , urology , immunology , kidney , lymphoma
Approximately 50% of patients with fibrillary glomerulonephritis (GN) progress to end-stage renal disease (ESRD) within 2 years of diagnosis, and no standard therapy exists. The data on rituximab therapy for fibrillary GN are limited and have inconsistent outcomes. Here, we report the largest case series to date using rituximab for fibrillary GN.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom